
Pharmaceutical Executive
Big Pharma's hiring slowdown is not translating into a growing demand for contract sales organizations.

Pharmaceutical Executive
Big Pharma's hiring slowdown is not translating into a growing demand for contract sales organizations.

Pharmaceutical Executive
Witnessing an industry's wild ride is perhaps the best reason to work for a business magazine. You've given us 25 years of excitement. And we plan to pay you back.

Pharmaceutical Executive
There was a time when Merck was looked upon as the granddaddy of all pharma companies. As the self-proclaimed oldest pharmaceutical and chemical company in the world, people wanted to work at Merck for its sterling reputation, excellent products, and job security.

Pharmaceutical Executive
As americans age, they are likely to suffer from more than one chronic condition at a time. So as the country's population grays, the rate at which patients presenting co-morbid indications will increase, as will the absolute number of patients whose treatment must be adjusted for more than one disease. These are not surprising facts, but they deserve careful consideration by pharma manufacturers and marketers.

Pharmaceutical Executive
Doctors and academics are praising Pfizer’s plan to allow the Cleveland Clinic to compare Celebrex with two NSAIDs. Is the company courageous, or is it taking to big of a risk?

Pharmaceutical Executive
A recent spate of false positive results using OraSure’s test has officials and company representatives scrambling to figure out what is causing these anomalies and how to stop them from impacting testing rates.

Medicus International has been successfully developing global communications for 30 years.

Many companies start up “eClinical” projects. But what is eClinical – and how does it support the R&D strategy?

Pharmaceutical Executive
The embattled pharma company needs to walk a tightrope between reassuring employees and pleasing investors. Can it succeed? Analysts and personnel experts share their insights.

Pharmaceutical Executive
The electronic revolution in clinical trials is still a work in progress, but researchers say it's time to bring EDC to the preclinical world.

Pharmaceutical Executive
A new understanding about how one class of bacteria protects itself from the environment could dramatically cut tuberculosis treatment time.

Pharmaceutical Executive
Medicare Part D launches. $23 billion worth of patents expire. FDA wrestles with safety issues. Pharma prepares for unprecedented cost cutting and restructuring. 2006 promises to be banner year-if you like roller coasters.

Pharmaceutical Executive
Some people are infected by HIV strains that are already resistant to FDA-approved drugs because they were transmitted by someone who developed resistance while receiving antiretroviral therapy. As a result, these patients often fail therapy.

Pharmaceutical Executive
Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and-at last-innovative mechanisms for troublesome targets.


Pharmaceutical Executive
The biggest threat to the success of polio eradication is Nigeria, where the immunization program was suspended on religious grounds in some parts of the country in 2003 and 2004.

Pharmaceutical Executive
Find out how you did on our December 2005 quiz.

Pharmaceutical Executive
Pargluva was a bad bet from early on. Analysts say so. Can BMS still save face?

Pharmaceutical Executive
Log on to CrazyMeds.org. Find out what patients say about your drugs, and what they think doctors and pharma don’t tell them.

Pharmaceutical Representative
A look at what the editors of Pharmaceutical Representative have planned for 2006.

Pharmaceutical Executive
Legal experts analyze the differences between the first two Vioxx trials and what allowed Merck to be successful this time around. They also offer insight about what to expect going forward.

Pharmaceutical Executive
The Critical Path is alive and well, as demonstrated by an agreement between FDA and Massachusetts-based BG Medicine to identify molecules associated with liver toxicity in animal trials.

PharmRep06Rates

PharmRep06Cal

PharmRep06CalRates

Pharmaceutical Executive
PhRMA Guiding Principle number 10 calls for the banishment of reminder ads. While there are many reasons why drug ads truly advance the public health, there are no good arguments for why reminder ads advance public health in any way.

Pharmaceutical Executive
Leo H. Sternbach's death feels like the end of an era, a time when the new drugs came easily and it was possible to have a huge impact on patients, then turn around and do it again.

Pharmaceutical Executive
Merck and GSK’s cervical cancer vaccines promise great benefits to women-but there are several key hurdles to clear before the drugs can become the blockbusters the companies are predicting. Analysts debate how long it will take it will take to overcome these obstacles.

Pharmaceutical Executive
Will vaccines against cervical cancer be the blockbusters that Merck and GSK are predicting? Or will issues of cost-effectiveness and parental reluctance hold them back? The experts weigh in on the debate.

Thomson CenterWatch recently launched a content management service to assist sponsors in complying with the latest requirements for clinical trial transparency. This web based program serves as a tool for sponsors to register their active clinical trials and publish their clinical trial results while following the data field guidelines established by clinicaltrials.gov and the World Health Organization and ICMJE.